Incidence of amyotrophic lateral sclerosis in Sicily: A population based study

PAOLO RAGONESE1, ELEONORA CELLURA1, PAOLO ARIDON1, MARCO D’AMELIO1, ROSELLA SPATARO1,2, ALFONSA CLAUDIA TAIHELLO1,2, DAVIDE MAIMONE3, VINCENZO LA BELLA1,2 & GIOVANNI SAVETTIERI1

1Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche, 2ALS Clinical Research Centre at the Department of Experimental Biomedicine and Clinical Neurosciences (Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche), University of Palermo, and 3Centro di riferimento regionale per le Malattie Neuroimmunologiche, UOC di Neurologia, Azienda Ospedaliera Garibaldi, Catania, Italy

Abstract

Our objective was to investigate incidence of amyotrophic lateral sclerosis (ALS) in Sicily, southern Italy, by means of a population based study. We included people with ALS resident in five Sicilian provinces, whose onset occurred in the two-year period 2005–2006 (population at 31 December 2006: 3,481,096 inhabitants). A multisource case-finding procedure was adopted and patients were classified as affected by ALS according to revised El Escorial criteria. During the two-year surveillance period, 97 patients meeting eligibility criteria included 57 males (58.8%) and 40 females (41.2%). Crude annual incidence rate was 1.4/100,000 person years (95% CI 1.33–1.47). The incidence rate was higher in males (1.71/100,000; CI 1.61–1.81) than in females (1.11/100,000; CI 1.01–1.21). Standardized incidence rate for the total population in the 45–74-years-old age group was 3.22 (CI 3.11–3.33). Prevalence rate was 6.0/100,000 (CI 5.97–6.03), higher in males (7.1/100,000; CI 7.02–7.18) than females (4.9/100,000; CI 4.86–4.94). In conclusion, ALS rates observed in the present study are higher in males than females, with a peak of incidence at 70 years of age in both genders. These findings are consistent with those of other population based European studies.

Key words: Amyotrophic lateral sclerosis, epidemiology, incidence, population based, Sicily

Introduction

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with an incidence range between 1.5 and 2.5 cases per 100,000 person-years (1). The mean survival time from onset of symptoms is approximately two years (1). Incidence based studies are expensive, and mortality studies have been used to obtain indirect estimates of ALS frequency (2–4). More recently, several studies have suggested that the validity of this methodology is questionable and several pitfalls may challenge the accuracy of official statistics data (5,6). Previous surveys performed in Italy indicated mean annual incidence rates ranging from 2.5 in Piedmont and Valle d’Aosta region, in northern Italy (7), to 1.6 in Apulia region, in southern Italy (8). Reported prevalence ranges from 1.56 observed in Sardinia (9) to 5.4 in Reggio Emilia (10) per 100,000 population. There is currently limited updated data on ALS frequency in southern Italy and in Sicily in particular, to offer the possibility of geographical comparison. We performed a survey in Sicily, which aimed to clarify the epidemiological and clinical features of ALS and to compare these data with those from other studies previously performed.

Methods

This study was conducted in Sicily, an island in southern Italy with nine administrative districts,
Incidence of ALS in Sicily

285

called provinces. The area covers 25,710 square kilometres. The population of the study area was 5,016,861 based on the Italian Statistics Bureau (ISTAT) data for the year 2006. In Sicily there are 35 neurological departments and three referral centres for ALS, located at the neurological departments of the university hospitals of Palermo, Catania and Messina. We studied ALS in five provinces (Agrigento, Caltanissetta, Catania, Palermo, Trapani), having previously ascertained that there was an adequate participation rate from physicians and from neurological departments in these provinces. The population of the five provinces considered was 3,481,096 inhabitants on 31 December 2006. The primary sources we targeted included neurological departments located in the study area and hospital discharge diagnosis data bank (HDDB). The search code used for diagnosis of ALS was 335.2 (International Classification of Disease, 10th revision). The regional registry for riluzole prescriptions was also used to trace patients who were subsequently interviewed and examined personally. Standardized face-to-face questionnaires with clinical information were used for this purpose. All of the forms were reviewed by neurologists expert in the field, who confirmed the diagnoses and decided for patients’ inclusion. ALS diagnoses were based on the revised version of the El Escorial criteria (11). These criteria distinguish four levels of diagnostic certainty: definite, probable, probable laboratory supported, and possible ALS. Cases with progressive muscular atrophy (PMA), primary lateral sclerosis (PLS), and progressive bulbar palsy (PBP) were included in the study and were reclassified according to the El Escorial criteria. We calculated crude, and age- and gender-specific incidence curves for patients whose onset occurred in the two-year period 2005–2006 (population at 31 December 2006: 3,481,096 inhabitants). Confidence limits (95% CI) for incidence rates were calculated assuming a normal distribution. The study is retrospective because case finding procedure was performed by analyses of all charts retrieved at the sources used for the study. All people who experienced their first symptoms during the study period were included in the incident cohort; those who died were not considered as prevalent cases unless death occurred before prevalence day. Comparison with other studies was possible for the age interval between 45 and 74 years. Standardized rates were also calculated using the direct method for this age group, with the 1990 U.S. population as a standard, to allow comparisons with previous studies (12). Since some underestimation was possible due to the methodology used, we also calculated completeness of the case-finding procedure and incidence rates according to the capture-recapture methodology by matching the records of hospital admission, the registries of ALS centres in Sicily, and the riluzole prescription registries.

Results

During the two-year surveillance period, 97 patients meeting the eligibility criteria were included: 57 males (58.8%) and 40 females (41.2%) with a male to female ratio of 1.4:1. Mean age at disease onset was 58.3 years (SD ± 14.6) and mean age at diagnosis was 59.5 years. There was a similar delay between males and females in the onset of symptoms and the diagnosis (mean 15.2 months for the whole cohort; 15.6 males, 14.5 females). Twelve patients were under 45 years of age (12.4%). No familial ALS cases were identified in the incident cohort. There were three patients with ALS-Frontal Temporal Dementia (ALS-FTD; 3.1%), three with PLS (3.1%) and four with PMA (4.1%). Almost 24% of patients had bulbar onset of symptoms and 70% of individuals had spinal onset. One patient (0.9%) experienced respiratory symptoms at onset while in 4.5% the type of onset was of uncertain classification. A higher rate of bulbar symptoms was noted among females (31.9%) than males (20.7%). Using the revised El Escorial diagnostic criteria, 69.4% of cases were classified as definite or probable, 5.4% were classified as laboratory supported, and 25.2% as possible (Figure 1). Crude
Table I. Annual gender- and age-specific incidence rates of amyotrophic lateral sclerosis in Sicily, southern Italy.

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Population</th>
<th>Cases</th>
<th>Rate</th>
<th>95% CI</th>
<th>Population</th>
<th>Cases</th>
<th>Rate</th>
<th>95% CI</th>
<th>Population</th>
<th>Cases</th>
<th>Rate</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–17</td>
<td>369,019.5</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>350,105.5</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>719,120</td>
<td>0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>18–24</td>
<td>161,532.5</td>
<td>1</td>
<td>0.31</td>
<td>0.03–0.65</td>
<td>157,547.5</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>319,080</td>
<td>1</td>
<td>0.16</td>
<td>0.09–0.40</td>
</tr>
<tr>
<td>25–34</td>
<td>236,511</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>252,273.5</td>
<td>3</td>
<td>0.59</td>
<td>0.33–0.86</td>
<td>488,784.5</td>
<td>3</td>
<td>0.31</td>
<td>0.11–0.50</td>
</tr>
<tr>
<td>35–44</td>
<td>250,587.5</td>
<td>2</td>
<td>0.40</td>
<td>0.13–0.67</td>
<td>267,026</td>
<td>4</td>
<td>0.75</td>
<td>0.49–1.01</td>
<td>517,613.5</td>
<td>6</td>
<td>0.58</td>
<td>0.39–0.77</td>
</tr>
<tr>
<td>45–54</td>
<td>212,902.5</td>
<td>11</td>
<td>2.58</td>
<td>2.32–2.84</td>
<td>229,575.5</td>
<td>5</td>
<td>1.09</td>
<td>0.82–1.36</td>
<td>442,478</td>
<td>16</td>
<td>1.81</td>
<td>1.62–2.00</td>
</tr>
<tr>
<td>55–64</td>
<td>178,182</td>
<td>16</td>
<td>4.49</td>
<td>4.25–4.73</td>
<td>195,566</td>
<td>10</td>
<td>2.56</td>
<td>2.29–2.83</td>
<td>373,748</td>
<td>26</td>
<td>3.48</td>
<td>3.30–3.66</td>
</tr>
<tr>
<td>75–84</td>
<td>89,539</td>
<td>7</td>
<td>3.91</td>
<td>3.55–4.27</td>
<td>129,894</td>
<td>4</td>
<td>1.54</td>
<td>1.19–1.89</td>
<td>219,433</td>
<td>11</td>
<td>2.51</td>
<td>2.25–2.76</td>
</tr>
<tr>
<td>85+</td>
<td>19,923</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>38,158</td>
<td>1</td>
<td>1.31</td>
<td>0.65–1.97</td>
<td>58,081</td>
<td>1</td>
<td>0.86</td>
<td>0.31–1.41</td>
</tr>
<tr>
<td>Total</td>
<td>1,667,047</td>
<td>57</td>
<td>1.71</td>
<td>1.61–1.81</td>
<td>1,798,693</td>
<td>40</td>
<td>1.11</td>
<td>1.01–1.21</td>
<td>3,465,740</td>
<td>97</td>
<td>1.40</td>
<td>1.33–1.47</td>
</tr>
</tbody>
</table>

Incidence rate among individuals over 18 years of age was 1.77 for the total population (CI 1.69–1.85); 2.20 (CI 2.09–2.31) in males, and 1.38 (CI 1.27–1.49) in females.

The annual incidence rate for ALS at the end of the observation period (2005–2006) was 1.4/100,000 person-years (95% CI 1.33–1.47). Incidence rate was higher in males (1.71; CI 1.61–1.81) than females (1.11; CI 1.01–1.21). This proportion of higher incidence in males remained similar at all age groups. There was some variability among the five provinces but no significant differences were detected. As illustrated in Figure 2, incidence showed a progressive increase up to age 75 years, and declined thereafter maintaining a similar trend in both genders with higher rates in males at all ages. Incidence rates of ALS in the five provinces considered are shown in Table I. We compared incidence rates in Sicily to those from previous studies with respect to the age range between 45 and 74 years by adjusting all the rates to the U.S. 1990 general population, as illustrated in Table II. Adjusted incidence rates for these age groups were 3.22/100,000 person-years (95% CI 3.11–3.33) in both genders: 4.3 in males (CI 4.13–4.41) and 2.27 in females (CI 2.11–2.43). We also calculated the prevalence rate of ALS on 31 December 2006. Crude prevalence was 6.0 per 100,000 population (CI 5.97–6.03): 7.1 in males (95% CI: 7.02–7.18), and 4.9 in females (CI: 4.86–4.94). By matching the three main sources of information according to the capture-recapture methodology, we estimated a rate of accuracy of our search strategy of 72.1%. Recalculating incidence rates according to these calculations would give an incidence rate of 1.95 per 100,000 population for the whole population considered (95% CI 1.88–2.02) and of 2.46 per 100,000 population for the population aged over 18 years (CI 2.39–2.53).

**Discussion**

Our study, performed in a southern Mediterranean island, used a retrospective cohort design to ascertain the occurrence of ALS according to diagnostic criteria adopted by several previous studies (13–15). The observed incidence rates were higher for males compared to females and showed a similar progressive increase up to 70 years of age in both genders, with a rapid decrease thereafter. Incidence rates observed in the present study are lower compared to those previously reported in Italy (1,7,8,13). This may be due at least in part to the retrospective nature of the study. To minimize a possible underestimation we focused our study on the health districts of Sicily with high participation rates by physicians and neurologists, and where it was possible to confirm each diagnosis by direct examination of patients and of clinical records. A previous report from a single Sicilian province has shown rates lower than expected and lower than those reported in other geographic areas (16). The reported annual incidence in that study was 0.44/100,000 inhabitants. It is likely that methodological differences may have influenced the results. At the time of the first study, performed in the province of Palermo, there were no disease archives and little information available for patients, particularly for rare conditions. In 1994, the El Escorial criteria were published (11), and although these criteria did not introduce specific instrumental
tests, it is likely that their use may have influenced estimates of incidence. The availability of riluzole therapy has also raised the level of disease awareness among physicians and consequently, the opportunity for possible ALS patients to come to neurologists’ attention. We included all four diagnostic levels of the revised version of El Escorial and included PLS and PMA in the calculation of the incidence and prevalence rates. These were classified as possible cases and accounted for a quarter of the total of ALS diagnoses. As has been previously noted, age-specific curves show a peak at about 70 years of age with a decline thereafter (17). This suggests the presence of environmental factors acting during specific critical periods of life. An alternative explanation is the possible underestimation of disease symptoms among these older individuals. Standardized rates adjusted for the 45–74 years age group as shown in Table II, make it easier to compare our results with those from previous studies performed in other geographic areas at different times (1,17,18). These comparisons give further strength to the fact that the observed rates reflect the real distribution of ALS in Sicily showing incidences that are lower, but close to, those of previous reports in Italy. One possible explanation for the different rates observed in our population may relate to the different historical background of the Sicilian population that can be considered genetically admixed. A previous study has suggested that genetic admixture could account for differential risks across populations for complex degenerative diseases such as ALS (19,20). However, we consider that a more probable explanation for the slightly lower incidence rates of ALS described in our study may be attributed to some underascertainment because of the retrospective data collection.

Acknowledgements

The authors thank Mario Zappia and Giovanni Majorana for their helpful collaboration. The authors also thank the anonymous referees for their contribution to a substantial revision and improvement of the study.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References